BioNTech BMS Collaboration: Pioneering Advances...

By João L. Carapinha

June 3, 2025

BioNTech and Bristol-Myers Squibb (BMS) have entered a landmark partnership to co-develop and co-commercialize BNT327. This bispecific antibody targets PD-L1 and VEGF-A, aiming to advance clinical development across multiple solid tumors, includin...
Pluvicto Prostate Cancer Trial: Phase III Results
Business Dynamics: How Novo Nordisk Lost GLP-1 Market Share
Tolebrutinib MS Analysis: Evaluating Economic Impact in SPMS
Alzheimer’s Blood Test Diagnostics: FDA Clears First Blood Test for Ear...
Another GLP-1 Drug Access Model: Will a Co-Pay Cap Revolutionize Affordability?
The Impact of MFN Pricing on the U.S. Biosimilar Market
Hepatitis Vaccine Uptake: Trends, Challenges, and the Role of Pharmacists
Biosimilars Price Competition: Impact on U.S. Pharmaceutical Pricing and Mark...
MFN Drug Pricing Targets: Lowering U.S. Drug Costs Through International Alig...
Drug Pricing Analysis: ICER’s Launch Price and Access Report Aims to En...
Trends in Anticancer Drug Pricing: Analyzing Medicare Launch Prices and Impac...
Publication Delays Impact Careers of Early-Career Researchers